These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 16263176)

  • 21. Statin therapy in the treatment of Alzheimer disease: what is the rationale?
    DeKosky ST
    Am J Med; 2005 Dec; 118 Suppl 12A():48-53. PubMed ID: 16356808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current approaches in the treatment of Alzheimer's disease.
    Shah RS; Lee HG; Xiongwei Z; Perry G; Smith MA; Castellani RJ
    Biomed Pharmacother; 2008; 62(4):199-207. PubMed ID: 18407457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropathology in Alzheimer's disease: target of pharmacotherapy.
    Souder E
    J Am Acad Nurse Pract; 2005 Mar; Suppl():3-5. PubMed ID: 16033022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of Alzheimer's disease].
    Bombois S; Lebert F; Vellas B; Pasquier F
    Rev Prat; 2005 Nov; 55(17):1913-9. PubMed ID: 16396232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic options in Alzheimer's disease.
    Moreira PI; Zhu X; Nunomura A; Smith MA; Perry G
    Expert Rev Neurother; 2006 Jun; 6(6):897-910. PubMed ID: 16784412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic and acquired immune responses in Alzheimer's disease.
    Britschgi M; Wyss-Coray T
    Int Rev Neurobiol; 2007; 82():205-33. PubMed ID: 17678963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M; Kálmán J
    Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anatomical and functional phenotyping of mice models of Alzheimer's disease by MR microscopy.
    Benveniste H; Ma Y; Dhawan J; Gifford A; Smith SD; Feinstein I; Du C; Grant SC; Hof PR
    Ann N Y Acad Sci; 2007 Feb; 1097():12-29. PubMed ID: 17413006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-modifying therapies in Alzheimer's disease.
    Salloway S; Mintzer J; Weiner MF; Cummings JL
    Alzheimers Dement; 2008 Mar; 4(2):65-79. PubMed ID: 18631951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective effect of rhubarb derivatives on amyloid beta (1-42) peptide-induced apoptosis in IMR-32 cells: a case of nutrigenomic.
    Misiti F; Sampaolese B; Mezzogori D; Orsini F; Pezzotti M; Giardina B; Clementi ME
    Brain Res Bull; 2006 Dec; 71(1-3):29-36. PubMed ID: 17113925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows.
    Praticò D
    Ann N Y Acad Sci; 2008 Dec; 1147():70-8. PubMed ID: 19076432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations.
    Farlow MR; Miller ML; Pejovic V
    Dement Geriatr Cogn Disord; 2008; 25(5):408-22. PubMed ID: 18391487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease.
    Lin HQ; Ho MT; Lau LS; Wong KK; Shaw PC; Wan DC
    Chem Biol Interact; 2008 Sep; 175(1-3):352-4. PubMed ID: 18573242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?
    Foster JK; Verdile G; Bates KA; Martins RN
    Mol Psychiatry; 2009 Mar; 14(3):239-51. PubMed ID: 18957942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.
    Maczurek A; Hager K; Kenklies M; Sharman M; Martins R; Engel J; Carlson DA; Münch G
    Adv Drug Deliv Rev; 2008; 60(13-14):1463-70. PubMed ID: 18655815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regression stage senile plaques in the natural course of Alzheimer's disease.
    Oide T; Kinoshita T; Arima K
    Neuropathol Appl Neurobiol; 2006 Oct; 32(5):539-56. PubMed ID: 16972888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
    Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD
    J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin.
    Ray B; Lahiri DK
    Curr Opin Pharmacol; 2009 Aug; 9(4):434-44. PubMed ID: 19656726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.